

Chunxi Zeng

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2978265/publications.pdf>

Version: 2024-02-01

16
papers

876
citations

759233

12
h-index

888059

17
g-index

17
all docs

17
docs citations

17
times ranked

1181
citing authors

#	ARTICLE	IF	CITATIONS
1	Intratumoral delivery of IL-12 and IL-27 mRNA using lipid nanoparticles for cancer immunotherapy. <i>Journal of Controlled Release</i> , 2022, 345, 306-313.	9.9	70
2	Construction of Messenger RNA (mRNA) Probes Delivered By Lipid Nanoparticles to Visualize Intracellular Protein Expression and Localization at Organelles. <i>Advanced Materials</i> , 2021, 33, 2103131.	21.0	6
3	Biomimetic nanoparticles deliver mRNAs encoding costimulatory receptors and enhance T cell mediated cancer immunotherapy. <i>Nature Communications</i> , 2021, 12, 7264.	12.8	55
4	Vitamin lipid nanoparticles enable adoptive macrophage transfer for the treatment of multidrug-resistant bacterial sepsis. <i>Nature Nanotechnology</i> , 2020, 15, 41-46.	31.5	159
5	Leveraging mRNA Sequences and Nanoparticles to Deliver SARS-CoV-2 Antigens In Vivo. <i>Advanced Materials</i> , 2020, 32, e2004452.	21.0	84
6	Functionalized lipid-like nanoparticles for in vivo mRNA delivery and base editing. <i>Science Advances</i> , 2020, 6, .	10.3	88
7	Formulation and Delivery Technologies for mRNA Vaccines. <i>Current Topics in Microbiology and Immunology</i> , 2020, , 71-110.	1.1	107
8	Rational Design of Small Molecules to Enhance Genome Editing Efficiency by Selectively Targeting Distinct Functional States of CRISPR-Cas12a. <i>Bioconjugate Chemistry</i> , 2020, 31, 542-546.	3.6	9
9	CRISPR-Cas12a Possesses Unconventional DNase Activity that Can Be Inactivated by Synthetic Oligonucleotides. <i>Molecular Therapy - Nucleic Acids</i> , 2020, 19, 1043-1052.	5.1	19
10	Chemotherapy drugs derived nanoparticles encapsulating mRNA encoding tumor suppressor proteins to treat triple-negative breast cancer. <i>Nano Research</i> , 2019, 12, 855-861.	10.4	39
11	Targeted delivery of atorvastatin via asialoglycoprotein receptor (ASGPR). <i>Bioorganic and Medicinal Chemistry</i> , 2019, 27, 2187-2191.	3.0	11
12	Design and assessment of engineered CRISPR-Cpf1 and its use for genome editing. <i>Nature Protocols</i> , 2018, 13, 899-914.	12.0	40
13	Synthetic Oligonucleotides Inhibit CRISPR-Cpf1-Mediated Genome Editing. <i>Cell Reports</i> , 2018, 25, 3262-3272.e3.	6.4	28
14	Lipid Polymer Hybrid Nanomaterials for mRNA Delivery. <i>Cellular and Molecular Bioengineering</i> , 2018, 11, 397-406.	2.1	57
15	Engineering CRISPR-Cpf1 crRNAs and mRNAs to maximize genome editing efficiency. <i>Nature Biomedical Engineering</i> , 2017, 1, .	22.5	95
16	GlcNAc Conjugated Atorvastatin with Enhanced Water Solubility and Cellular Internalization. <i>Bioconjugate Chemistry</i> , 2017, 28, 2109-2113.	3.6	3